https://www.bms.com/

Contact Information:

Jill Cohen (AZ)
Phone: 602-570-4329
Jill.Cohen@bms.com

Gabe Golden (MN)
Phone: 651-235-6958
Gabriel.Golden@bms.com

Available on TEAMS  throughout the conference as noted on program during log in time each morning and breaks.

 

Virtual Exhibit Hall Home

Bristol Myers Squibb is committed to the development of transformational therapeutics for patients with neurodegenerative and neuromuscular diseases.

We have built a network of external partnerships across multiple treatment platforms (small molecules, biologics and nucleic acid targeting) that leverage our leadership in protein homeostasis, immunology and inflammation to attack neurological and neuromuscular diseases.

Areas of interest include, but are not limited to, the following approaches:

• Disease-modifying therapies for neurodegenerative, neuroimmune, neuroinflammatory and neuromuscular diseases (e.g., Alzheimer’s, Parkinson’s, and Lou Gehrig’s diseases, Multiple Sclerosis, repeat expansion diseases, muscular dystrophies)
• Targets that modulate protein homeostasis, protein clearance, immune system biology, inflammation and reduce or eliminate toxic protein production
• Emerging technologies (RNA, DNA targeting, gene regulation, editing and replacement, vector optimization) that when matched to underlying disease genetics, can deliver a precision medicine portfolio with a high probability of success to address unmet medical needs
• Targets in sporadic and orphan/rare neurological and neuromuscular diseases
• Translational tools and technologies such as neuroimaging and fluid biomarkers to track neurodegenerative disease
• Novel blood brain-barrier delivery technologies

Zeposia

Zeposia Visual Aid

Zeposia Getting Started Info